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Summary 
The protein kinase MOlWZDK7 has recently been 
shown to be associated with the general transcription 
factor TFIIH and to be capable of phosphorylating the 
RNA polymerase II carboxy-terminal domain. Here, we 
show that a monoclonal MOlWCDK7 antibody coim- 
munoprecipitates, from a rat liver nuclear extract, all 
components of the RNA polymerase II transcription 
apparatus required for initiation at the albumin and 
adenovirus major late promoters. The immunoprecipi- 
tate includes RNA polymerase II, TFIID, TFIIB, TFIIH, 
TFIIF, and TFIIE, but is devoid of transcriptional activa- 
tor proteins, such as HNFl, HNF4, and CIEBPa. The 
finding of an autonomously initiating RNA polymerase 
II holoenzyme in mammalian cells suggests concep- 
tual similarities between transcription initiation in pro- 
karyotes and eukaryotes. 
Introduction 
Transcription initiation can be divided into three major 
steps: initiation complex assembly, isomerization, and 
promoter clearance (McClure, 1980; Knaus and Bujard, 
1990; Eick et al., 1994; Goodrich and Tjian, 1994). In the 
first step, RNA polymerase and ancillary proteins bind re- 
versibly to promoter DNA to form the closed complex. In 
the second and nearly irreversible step, a short stretch 
of DNA around the transcription initiation site becomes 
unwound and serves as a template for abortive transcrip- 
tion, the synthesis of short oligoribonucleotides. Finally, 
in the third step, the RNA polymerase leaves the promoter 
to elongate the primary transcript. 
In Escherichia coli, closed complex assembly consists 
of the binding to the promoter of the RNA polymerase 
holoenzyme, composed of the initiation factor o and the 
four core enzyme subunits (& [3’, and 6. After isomeriza- 
tion and during promoter escape, o dissociates from the 
elongating core enzyme. The efficiency of each of the 
three initiation steps can be subject to regulation by tran- 
scriptional activator or repressor proteins binding to spe- 
cific operator sequences in the proximity of the promoter. 
Moreover, the same regulatory protein can affect different 
initiation steps, depending on the precise promoter con- 
text. For example, the catabolite activator protein (CAP) 
enhances closed complex formation at the lac promoter, 
stimulates isomerization at the gal promoter, and facili- 
tates promoter escape at the ma/T promoter (Menendez 
et al., 1987; for reviews see Kolb et al., 1993; Busby and 
Ebright, 1994). 
For protein-encoding genes of eukaryotic cells, tran- 
scription initiation involves over 40 polypeptides. These 
include the 12 subunits of RNA polymerase II (pol II), the 
general transcription factors (GTFs) TFIIA, TFIIB, TFIID, 
TFIIE, TFIIF, TFIIH, and TFIIJ (for reviews see Roeder, 
1991; Maldonado and Reinberg, 1995) and, at least in 
yeast, a number of additional proteins called SRBs (for 
suppressors of RNA polymerase B) (Koleske et al., 1992; 
Thompson et al., 1993; Liao et al., 1995). Most of the GTFs 
are themselves composed of multiple subunits. For in- 
stance, TFIID, a particularly important component in pro- 
moter recognition, consists of the TATA box-binding pro- 
tein (TBP) and at least eight TBP-associated factors, called 
TAFs (Dynlacht et al., 1991; Kokubo et al., 1994). Based 
on in vitro reconstitution studies with purified components, 
initiation complex assembly has originally been proposed 
to occur in multiple discrete steps. In this model, TFIID, 
TFIIA, and TFIIB associate with the promoter to form the 
DAB preinitiation complex, before pol II and the remaining 
GTFs associate to complete the initiation complex (for re- 
views see Roeder, 1991; Corden, 1993; Maldonado and 
Reinberg, 1995). Transcriptional activator or repressor pro 
teins may mediate their effect through protein-protein inter- 
actions with GTFs, such as TBP (Truant et al., 1993), TAFs 
(Goodrichetal., 1993; Gilletal., 1994; Chiangand Roeder, 
1995), TFIIB (Roberts and Green, 1994; Kim and Roeder, 
1994), and TFIIH (Xiao et al., 1994; Drapkin and Reinberg, 
1994). 
A novel perspective on eukaryotic transcription has re- 
cently been opened through the discovery of a holoen- 
zyme in yeast (Koleske and Young, 1994; Kim et al., 1994; 
for review see Emili and Ingles, 1995). The largest pol II 
subunit harbors a carboxy-terminal domain (CTD) com- 
posed of 26 (yeast) to 52 (mammals) repeats of the hepta- 
peptide YSPTSPS or minor permutations thereof (Corden, 
1990; Young, 1991). Elegant genetic studies by Young 
and coworkers (Koleske et al., 1992; Thompson et al., 
1993; Liao et al., 1995) have identified the CTD as a target 
for interaction with new components of the pol II transcrip- 
tion machinery, SRBs. These novel proteins were found 
to be associated with a large complex, containing pol II, 
TFIIB, TFIIF, TFIIH (Koleske and Young, 1994; Kim et al., 
1994), and, depending on the purification procedure, TBP 
(Thompson et al., 1993). When complemented with TBP 
and TFIIE, this large complex, named holoenzyme, was 
capable of efficient and accurate in vitro transcription 
(Koleske and Young, 1994). 
The serines of the CTD are targets for extensive phos- 
phorylation by a number of protein kinases (for review see 
Corden, 1993). One of these CTD kinases is associated 
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with human TFIIH and has recently been identified as 
M015ICDK7 (Roy et al., 1994; Serizawa et al., 1995; 
Shiekhattar et al., 1995). A structurally related kinase, 
KIN28, is similarly associated with yeast TFIIH (Feaver 
et al., 1994). Biochemical evidence suggests that CTD 
phosphorylation may be required for promoter clearance. 
First, the CTD of elongating but not “free” pol II is highly 
phosphorylated (Corden, 1993; Wuarin and Schibler, 
1994), and second, unphosphorylated, but not phosphory- 
lated, CTD binds avidly to TBP (Usheva et al., 1992). How- 
ever, successful in vitro transcription can be accomplished 
without CTD phosphorylation (Serizawa et al., 1993) 
opening room for other speculations. 
Given the high evolutionary conservation of compo- 
nents of the pol II transcription apparatus, it is likely that 
the holoenzyme is a general feature of eukaryotic cells. 
Yet, the existence of such a complex has not yet been 
reported in mammalian cells. By using a monoclonal 
M015/CDK7 kinase antibody (Tassan et al., 1994) we 
were able to immunoprecipitate a pol II holoenzyme from 
rat liver nuclear extracts. The immunopurified complex 
contains all of the components required for efficient and 
promoter-specific initiation on linear and circular tem- 
plates. 
Results 
The CTD Kinase M015/CDK7 Is Associated with a 
Pol I l.Holoenzyme 
M015/CDK7, in conjunction with cyclin H and an addi- 
tional protein (p36), has originally been described as a 
cyclin-dependent kinase (CDK)-activating kinase (Fesquet 
et al., 1993; Fisher and Morgan, 1994; Solomon et al., 
1993; Poon et al., 1993; Tassan et al., 1994; Makela et 
al., 1994). Recently, the same M015/CDK7 kinase com- 
plex has also been identified as the TFIIH-associated CTD 
kinase (Royet al., 1994; Serizawaet al., 1995; Shiekhattar 
et al., 1995). This feature makes this kinase a likely candi- 
date for a regulator of transcription by pol II. Since M015/ 
CDK7 kinase has been studied mostly in rapidly dividing 
cells, we examined whether it also accumulates in nonpro- 
liferating, terminally differentiated cells, such as rat paren- 
chymal hepatocytes. lmmunoblot analysis of transcrip- 
tionally competent rat liver nuclear extracts with the 
monoclonal antibody MO-l.1 revealed the presence of 
MO1 5/CDK7 (Figure 1 B, lane 3). We then used the MO-1 .l 
antibody to immunoprecipitate M015/CDK7, to examine 
whether TFIIH subunits and perhaps other components 
of the pol II machinery would be associated with this ki- 
nase. To this end, MO-l.1 antibodies were adsorbed to 
paramagnetic beads impregnated with goat anti-mouse 
antibodies, and the resulting beads were incubated with 
a cleared liver nuclear lysate. The beads were then con- 
centrated by magnetic attraction and washed three times 
extensively with a large excess of binding buffer con- 
taining the nonionic detergent Triton X-100. The proteins 
present in the immunoprecipitate (IP) were separated by 
SDS-polyacrylamide gel electrophoresis (SDS-PAGE) 
and subjected to Western blot analysis with various anti- 
bodies against general components of the pol II transcrip- 
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Figure 1. A Monoclonal MO15 Kinase Antibody lmmunoprecipitates 
a Complex Containing Several Components of the Pol II Transcription 
Machinery 
MO15 kinase, and proteins associated with it, were immunoprecipi- 
tated with the monoclonal antibody MO-1 .I from liver nuc!ear extract 
and analyzed by SDS-PAGE, Coomassie blue staining (A), and immu- 
noblotting (E). As a negative control, immunoprecipitation was con- 
ducted in parallel with an equal amount of an irrelevant monoclonal 
antibody (anti-NANP). 
(A) Coomassie blue-stained proteins. Lane 1, MO-l .l-immunoprecip- 
itated proteins from 400 pg (50 ~1) of nuclear extract (NE); lane 2, 
anti-NANP immunoprecipitated proteins from 400 ng (50 ~1) of nuclear 
extract; lane 3, 80 ng of NE: lane 4, 20 ng of NE; lane 5, 5 ng of NE; 
lane 6, 1.25 pg of NE; lane 7, 0.4 ng of NE. 
(B) Western blots. Lanes 1 and 2, immunoprecipitated proteins recov- 
ered from 200 ng (25 nl) of nuclear extract with the monoclonal antibod- 
ies MO-1 .l and anti-NANP, respectively; lane 3,40 pg of NE. Antibod- 
ies used in the Western blots are indicated at left. Nuclear proteins 
were separated on 10% polyacrylam ide gels, except for REP1 and TAFssO 
immunoblots, for which 7% polyacrylamide gels were used. Note that 
in the immunoblots with nuclear extracts the TAFSs and TFIIFnnp30 anti- 
bodies strongly cross-react with unrelated proteins (CRM for cross- 
reactive material) that disappear during immunoprecipitation with the 
MO-1 .l antibody. 
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Figure 2. MO-1 .l Antibody Coimmunoprecipitates Only the IIA Iso- 
form of Pol II 
(A) A nuclear extract (lane i), an SDS nuclear lysate (lane 2) and an 
MO-1 .l IP (lane 3) were displayed on a 7% SDS-polyacrylamide gel 
and probed by Western blotting with a monoclonal CTD antibody. The 
positions of the three forms of the largest pol II subunit, RPBl, are 
indicated. 
(B) A nuclear extract, particularly rich in pol IIB (lane 3), was used 
in immunoprecipitations with MO-1 .l (lane 1) and anti-CTD (lane 2) 
antibodies. The proteins were analyzed as described in (A). 
tion apparatus. As a negative control, immunoprecipita- 
tion with an unrelated monoclonal antibody, recognizing 
multimers of the tetrapeptide NANP, was performed. From 
the Coomassie blue-stained gel shown in Figure lA, we 
estimated that less than 0.4% of the input nuclear lysate 
bound nonspecifically to the magnetic beads. As ex- 
pected, the MO1 5/CDK7 IP contained more than 50% of 
the MOlUCDK7 kinase present in the input rat liver nu- 
clear lysate (Figure 1 B, lanes 1 and 3). In accordance with 
the association of M015/CDK7 with TFIIH suggested by 
previous reports, the IP was also enriched in p62 (Fischer 
et al., 1992) a subunit of TFIIH (Figure 18, lane 1). Re- 
markably, however, the MO-l .l antibody also coimmuno- 
precipitated a sizable proportion of other essential pol II 
transcription components, such as the largest polymerase 
subunit, RPBl, and the GTFs TBP, TAF2%, TAFeo, TAFs5, 
TFIIB, TFIIFRAP30, and TFllEa (Figure 1 B, lane 1). None of 
these constituents are enriched with the magnetic beads 
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carrying the control monoclonal antibody (Figure 1 B, lane 
2). One concern with the immunoprecipitation of a large 
multisubunit complex like the one described here is that 
DNA-binding components, such as TFIID and pol II sub- 
units, could be artificially tethered together by contaminat- 
ing DNA. However,  as will be shown below, this does not 
seem to be the case. 
Three pol II RPBl forms with different electrophoretic 
mobilities have been described: pol IIA, pol IIB, and pol 
II0 (for reviews see Corden, 1990; Young, 1991). Pol II0 
bears a highly phosphorylated CTD and is predominantly 
associated with elongating ternary transcription com- 
plexes (Wuarin and Schibler, 1994; for review see Corden, 
1993). Pol IIA is not or only partially phosphorylated and 
is the major form observed in soluble nuclear extracts. 
This is believed to be the initiation-competent form of pol 
II. Pol IIB lacks part of its CTD and may thus be a partial 
proteolytic degradation product of either pol IIA or pol II0 
(for review see Dahmus, 1994). The proportion of pol IIB is 
somewhatvariable in different nuclear lysates (see below), 
further suggesting that it may be the result of artifactual 
degradation. Figure 2A shows that both pol II0 and pol 
IIA are present in an SDS lysate of entire liver nuclei (lane 
2). The transcription competent extract, obtained by ex- 
traction of liver nuclei with 0.4 M NaCI, is devoid of highly 
phosphorylated polllO, but contains pol IIA and somewhat 
variable amounts of pol IIB (Figure 2A, lane 1; Figure 2B, 
lane 3). Interestingly, pol IIA is the only polymerase in the 
MO-l.1 IP (Figure 2A, lane 3; Figure 28, lane l), sug- 
gesting that an intact CTD is required for the association 
of the M015/CDK7 kinase complex with the polymerase. 
For the experiment shown in Figure 26, we deliberately 
chose a nuclear extract in which pol II8 was relatively 
abundant (lane 3). This extract was also used for an immu- 
noprecipitation with a monoclonal anti-CTD antibody. As 
shown in Figure 2B (lane 2), this antibody selectively pre- 
cipitated pol IIA, although in the Western blot it still recog- 
nized the residual CTD associated with pol IIB (Figure 
28, lane 3). Thus, in the context of unfractionated nuclear 
extract, only the carboxy-terminal portion of the CTD may 
be accessible. Surprisingly, the MO-l .l antibody yielded 
a higher proportion of the pol IIA present in the nuclear 
extract than the CTD antibody. We cannot discern whether 
this reflects differences in the affinities of the two antibod- 
ies to their respective epitopes, or whether the CID in the 
large complex is poorly accessible to the antibody. 
An interesting but yet unresolved question concerns the 
regulation of CTD phosphorylation by MO1 5/CDK7. If this 
kinase is closely associated with the CTD, why does it not 
convert pol IIA into pol I IO? One possibility would be that 
the CTD kinase only becomes activated when the holoen- 
zyme is bound to the promoter. At least in vitro, this does 
not seem to be the case. The immunoprecipitated M015/ 
CDK7 kinase is highly active on an exogenously added 
glutathione S-transferase (GST)-CTD fusion protein (Fig- 
ure 3), as well as on the CTD of the coimmunoprecipitated 
pol II (data not shown). To examine whether phosphoryla- 
tion on the multiple CTD repeats occurs cooperatively, 
[Y-~~P]ATP and cold ATP were added at a relatively low 
Figure 3. CTD Kinase Activity in the MO-l ,1 IP 
Portions (from 5 pl of nuclear extract) of the MO-1 .l (lanes 2, 3, 5, 
and 6) and NANP (lanes 1 and 4) IPs were incubated with IO uCi 
lv-32P1ATP, 15 uM cold ATP, and a GST-CTD fusion protein (about 
iO0 nM). After‘20 min, the kinase reactions shown in’lanes 1: 2, 4, 
and 5 were stopped by the addition of SDS-PAGE loading buffer. The 
kinase reactions shown in lanes 3 and 6 were continued for 20 min 
in the presence of 5 mM cold ATP. The proteins were fractionated by 
SDS-PAGE, stained by Coomassie blue (lanes 1,2, and 3) or exposed 
for autoradiography (lanes 4, 5, and 6; for 20 s). 
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B C Figure 4. In Vitro Transcription with the Immu- 
2 3 4 5 6 1 2 1 2 nopurified Pol II Holoenzyme 
(A) A supercoiled circular G-free cassette tem- 
plate containing the adenovirus major late pro- 
-170 Alb400 + 4- AdML400 moter (AdMLPOO, -400 to +I 0) was incubated 
AdML200 + 
with the following: lane 1, MO-1 .I-immunopre- 
cipitated proteins from 400 ng (50 cl) of nuclear 
extract (NE); lane 2, anti-NANP immunoprecip- 
itated proteins from 400 Kg (50 ~1) of nuclear 
:. extract; lane 3, 80 ng of NE; lane 4, 20 frg of 
‘* NE; lane 5, 5 trg of NE; lane 6, 1.25 frg of NE. 
3, (8) Two supercoiled circular G-free cassette templates containing either the adenovirus ma- 
I 
::, $ jor late promoter (AdMLPOO, -400 to +lO) or 
AdML.760 + 9AdML200 
the albumin promoter (- 170Alb400, -170 to 
+22) were incubated with immunoprecipitated 
proteins from 400 ug of nuclear extract. Lane 
1, anti-NANP IP (control); lane 2, MO-1 .l IP. 
(C) A linear G-free cassette template, 
AdML400, and a supercoiled circular G-free cassette template, AdML200, both containing adenovirus major late promoter sequences encompassing 
nucleotides -400 to +lO ware incubated with immunoorecioitated proteins from 400 pg of nuclear extract. Lane 1, anti-NANP IP (control); lane 
2, MO-l.1 IP. 
total concentration of 15 PM in a phosphorylation reaction 
with 100 nM of GST-CTD fusion protein. Given that the 
CTD contains approximately 100 serine residues that can 
potentially be phosphorylated, this kinase reaction was 
performed at a ratio of approximately 0.75 phosphoaccep- 
tor sites per phosphate donor ATP. Consistent with this 
ratio, phosphorylation of the GST-CTD fusion protein did 
not affect the mobility of the bulk protein significantly (Fig- 
ure 3, lane 2). In contrast, autoradiography of the same 
gel revealed that an appreciable proportion of radiolabeled 
GST-CTD protein shifted to lower mobilities (Figure 3, 
lane 5). In fact, some of these phosphorylated GST-CTD 
molecules reached the position observed in the kinase 
reaction in which the ATP concentration was increased 
to 5 mM, after the initial labeling at 10 nM (Figure 3, lanes 
3 and 6). This observation indicates that an already phos- 
phorylated CTD is a better su bstrate for further phosphory- 
lation than an unphosphorylated CTD. Given that CTD 
phosphorylation can take place in the absence of promoter 
DNA, kinetic parameters are likely to be responsible for the 
lack of CTD phosphorylation in pol IIA (see Discussion). 
The lmmunopurified Holoenzyme Contains 
All Components Required for 
Promoter-Specific Transcription 
Having demonstrated the existence of a mammalian pol 
II complex containing many essential GTFs, we wondered 
whether this complex was capable of accurate transcrip- 
tion initiation, similar to the E. coli RNA polymerase holo- 
enzyme. Therefore, we incubated the MO-l  .l (Figure 4A, 
lane 1) and NANP (Figure 4A, lane 2) immunoprecipitated 
proteins and the same dilutions of nuclear extract shown 
in Figure 1A (Figure 4, lanes 3-6) with a G-free cassette 
template harboring the adenovirus major late promoter, 
along with the three nucleoside triphosphates ATP, CTP, 
and [a-32P]UTP. Figure4Ademonstrates thatthistemplate 
is actively transcribed by the immunopurified pol II holoen- 
zyme (lane 1). Asexpected on the basisof the immunoblot- 
ting results described in Figure 1 B, no transcripts can be 
discerned in the transcription reaction with the control IP 
(Figure 4A, lane 2). With 80 ug and 20 pg of nuclear pro- 
teins, similar amounts of in vitro transcripts are observed 
as with the immunopurified enzyme (Figure 4A, lanes 3 
and 4). However, no transcripts can be discerned with 5 
ugor 1.25 pgof nuclear proteins(Figure4A, lanes5and 6). 
On the basis of Figure 1 A, we estimate that the magnetic 
beads are contaminated by no more than 1.5 vg (0.4% 
of input proteins), an insufficient amount for in vitro tran- 
scription (see above). Thus, the strong signal obtained 
with the immunopurified nuclear proteins (Figure 5, lane 
1) cannot be accounted for by fortuitous contamination of 
the magnetic beads bycomponentsof the pol II machinery. 
We also wanted to test the ability of the immunopurified 
holoenzyme to transcribe from the promoter of a cellular 
gene. Therefore, the IPs were incubated with a G-free 
cassette template harboring the albumin promoter (Gorski 
et al., 1986), in addition to the adenovirus major late tem- 
plate. Figure 4B shows that these two promoters are effi- 
ciently transcribed, although the adenovirus major late 
promoter appears to be somewhat more active. 
Since our in vitro transcriptions were performed with 
circular supercoiled templates and since negative su- 
percoiling has been described to facilitate transcription 
initiation (Parvin and Sharp, 1993; Goodrich and Tjian, 
1994), we wished to determine whether linear templates 
are also transcribed by the immunoprecipitated complex. 
To this end, a circular and a linearized adenovirus late 
promoter plasmid were provided as templates for the im- 
munoenriched complex. As shown in Figure 4C, the holo- 
enzyme initiates accurately at both promoters, although 
the circular template produces about 3-fold more tran- 
scripts than the linear plasmid. 
An issue that had to be addressed is whether compo- 
nents of the holoenzyme may be tethered together by DNA 
present in the nuclear extract, and if so, whether such 
interactions are required for the coimmunoprecipitation 
with the MO-1 .l antibody. The IP from 0.5 mg of nuclear 
proteins did not contain nucleic acids in amounts detect- 
able by ethidium bromide staining after agarose gel elec- 
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Figure 5. The Pol II Holoenzyme Can Be Purified in the Presence of 
Distamycin 
(A) Electrophoretic mobility shift assays of human recombinant TBP 
(2 ng/lO VI reaction) and a double-stranded oligonucleotide spanning 
the AdML TATA box (4 ng/lO ~1 reaction) in the presence (lanes 2-4) 
and absence (lane 1) of distamycin. Only the polyacrylamide gel region 
containing the protein-DNA complex is shown. 
(B) In vitro transcription from the AdML promoter in crude nuclear 
extracts in the presence (lanes 2-4) and absence (lane 1) of dista- 
mycin. In vitro transcriptions were performed as the one shown in 
Figure 4A, lane 3. 
(C) In vitro transcription from the AdM L promoter with pol II holoenzyme 
immunopurified in the presence (lanes 2-4) and absence (lane 1) of 
distamycin. The IPswere washed with buffer lacking distamycin before 
they were used for in vitro transcriptions. In vitro transcriptions were 
performed as the one shown in Figure 4A, lane 1. 
trophoresis (data not shown). However, short heteroge- 
neous DNA fragments, present at stoichiometric amounts 
with coimmunoprecipitated TBP, would probably have es- 
caped detection by this method. We thus designed a more 
sensitive strategy to examine whether DNA is involved in 
the coimmunopurification of TBP. Distamycin, a drug with 
high affinity to AT-rich sequences in the minor groove of 
DNA, strongly competes with TBP for DNA binding 
(Chiang et al., 1994). As shown in Figure 5A (lanes 3 and 
4), distamycin, at concentrations of 2.5 PM and 25 PM, 
severely interferes with the binding of TBP to a double- 
stranded oligonucleotide encompassing the TATA box of 
the adenovirus major late promoter. Consistent with this 
observation, in vitro transcription from the adenovirus ma- 
jor late promoter in liver nuclear extracts is completely 
abolished at distamycin concentra0ons of 2.5 or 25 PM 
(Figure 5B, lanes 3 and 4). Yet, the same drug has little, 
if any, effect on the immunoselection of the pol II holoen- 
zyme with the MO-l.1 antibody, even when present at 
25 PM. As demonstrated in Figure 5C, similar levels of 
adenovirus major late transcripts were synthesized by the 
pol II holoenzyme, irrespective of whether distamycin was 
included during its immunopurification (lanes 2-4) or not 
(lane 1). Therefore, DNA is unlikely to tie TFIID to the 
multisubunit complex described here. However,  whether 
DNA is involved in the assembly, stabilization, or both of 
pol II holoenzyme in vivo remains an open question. 
In conclusion, the results described in this section dem- 
onstrate that the rat liver pol II holoenzyme described here 
is capable of accurate in vitro transcription of linear and 
circular templates, and from two distinct promoters. Thus, 
the immunopurified mammalian holoenzyme contains all 
basal constituents for initiation complex assembly, iscmer- 
ization, and promoter clearance. 
Sequence-Specif ic Transcription Factors Do Not 
Copurify with the Holoenzyme 
The activation domains of several transcriptional regula- 
tory proteins have been shown to establish specific pro- 
tein-protein interactions with various components of the 
pol II transcriptional machinery. Among the targets for 
such interactions are TBP (Truant et al., 1993), TAFs 
(Goodrich et al., 1993; Gill et al., 1994; Chiang and Roeder, 
1995), TFIIB (Kim and Roeder, 1994; Roberts and Green, 
1994), and TFIIH. (Xiao et al., 1994). Since, as shown 
here, all of these components appear to be part of the 
mammalian pol II holoenzyme, we wondered whether 
DNA-binding transcriptional regulatory proteins copurify 
with the holoenzyme. We thus examined the MO-l .l im- 
munoprecipitated proteins for the presence of the three 
liver-enriched transcription factors HNFl (Lichtsteinerand 
Schibler, 1989), HNF4 (Tian and Schibler, 1991), and 
ClEBPa (Landschulz et al., 1989). The data displayed in 
Figure 6A demonstrate that none of the three transcription 
factors could be detected in the IP. Thus, either the three 
examined transcriptional activator proteins are present in a 
large excess over the holoenzyme, or the affinity between 
transcriptional activators and components of the holoen- 
zyme are insufficient to withstand the immunoprecipita- 
tion, or both statements are true. If the holoenzyme is not 
associated with transcriptional activators, it should tran- 
scribe equally well from a core promoter, devoid of cis- 
acting upstream elements, and a promoter carrying such 
binding elements for activators. We chose the albumin 
promoter to test this conjecture. This promoter has been 
extensively studied in vitro (Gorski et al., 1986; Licht- 
Steiner at al., 1987; Maire et al., 1989) and in vivo (Heard 
et al., 1987) and has been demonstrated to be composed 
of the core promoter and six upstream elements, A to F, 
binding liver-enriched and ubiquitous transcription fac- 
tors. Two such factors, HNFl and C/EBP, occupying sites 
B and D, respectively, are particularly important for liver- 
specific albumin in vitro transcription. Two G-free cassette 
templates, -59Alb400 and -170Alb220, have been con- 
structed that contain different lengths of albumin 5’-flank- 
ing sequences. The truncated promoter of the template 
-59Alb400 lacks both the HNFl and ClEBP recognition 
sequences. Not surprisingly, this promoter is much less 
active than the full-length promoter of -170Alb220 in in 
vitro transcription assays with a crude liver nuclear extract 
(Figure 6B, lane 1). In contrast, and in accordance with 
the immunoblot data presented in Figure 6A, the upstream 
albumin promoter region has little impact on the in vitro 
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Figure 6. The Pol II Holoenzyme InitiatesTranscription in the Absence 
of Transcriptional Activator Proteins 
(A) lmmunoprecipitates from 200 ug of nuclear extract were examined 
in Western blot experiments for the presence of the transcriptional 
activator proteins CIEBPa, HNF4, and HNFl: 10% SDS-polyacryl- 
amide gelswere usedforC/EBPu and HNF4; 7% SDS-polyacrylamide 
gels were used for HNFl. Lanes 1, MO-l .I IPs; lanes 2, anti-NANP 
IPs; lanes 3, 40 Kg of nuclear extract. 
(B) Two circular albumin promoter G-free cassette templates that do 
(-170Alb220) or do not contain (-59Alb400) upstream binding sites 
for sequence-specific transcription factors were in vitro transcribed 
with liver nuclear extract(lane I), MO-1 .l immunoprecipitated proteins 
from 400 pg of nuclear extract (lane 2) or anti-NANP immunoprecipi- 
tated proteins (lane 3). 
transcription with the immunopurified pol II holoenzyme 
(Figure 6B, lane 2). 
The results presented in this section suggest that the 
holoenzyme is not associated with significant levels of 
transcriptional activator proteins and, hence, is not stimu- 
lated by the presence of upstream promoter elements. 
We report here the successful isolation of a pol II holoen- 
zyme from a rat liver nuclear extract, by using a mono- 
clonal antibody against the M015/CDK7 kinase. This en- 
zyme contains all of the components required for accurate 
transcription initiation and elongation. Our  immunoblotting 
data suggest that a significant fraction of each, RPBl (the 
largest pol II subunit), TBP, TA!&, TAF8,,, TAF5,,, TFIIB, 
TFIIH (MO1 5/CDK7), TFlIFRAP30r and TFIIE (subunit a), are 
immunoprecipitated with the MO-l.1 antibody. We esti- 
mated that, in intact nuclei, these proteins are about 30- 
fold more concentrated than in the nuclear extract used 
Figure 7. Cartoon Representing the Mammalian Pol II Holoenzyme 
The core enzyme, consisting of 12 subunits, is associated with GTFs 
to form the transcription initiation competent holoenzyme. Only those 
GTFs are shown for which the presence of at least one subunit has 
been directly documented (Figure 1 B). For multimeric GTFs, the exam- 
ined subunits are indicated. The topological arrangement of GTFs 
within the complex are unknown, but direct interactions between TBP 
and TFIIB, CTD, and TAFs have been reported (see text). 
for the immunoprecipitation. We would thus not be sur- 
prised if, in vivo, the majority of the above mentioned poly- 
peptides were assembled into a large pol II holoenzyme 
complex, as schematically shown in Figure 7. It should 
be mentioned in this context that M015/CDK7 may inter- 
act with pol II not solely via its association with TFIIH. 
In an immobilized protein interaction assay, the putative 
yeast homolog of MOlVCDK7, KIN28, binds directly to 
RPBl and RPBP, the two largest pol II subunits (Feaver 
et al., 1994). Conceivably, the pol II holoenzyme complex 
may contain additional constituents, for example the mam- 
malian counterparts of yeast SRB proteins (for review 
see Koleske and Young, 1995). This issue can be ad- 
dressed as soon as antibodies for these constituents be- 
come available. 
Since the antibody used in the immunoprecipitation was 
directed against MOlVCDK7 and since this kinase is 
tightly associated with TFIIH, one would expect higher 
recoveries for M015/CDK7and theTFllH subunit p62 than 
for other components of the holoenzyme. Although this is 
indeed the case, it is well possible that M015/CDK7 (and 
its associated subunits) also exists as separate entities 
that perform tasks unrelated to transcription. As men- 
tioned above, the MO1 5/CDK7-cyclin H,p36 complex had 
originally been discovered as aCDK-activating kinase. Us-  
ing in vitroassays, no M015/CDK7 kinase activity changes 
could be monitored during cell cycle progression (Tassan 
et al., 1994). Hence, the precise role, if any, of this kinase 
in proliferation control is still unclear. But, M015/CDK7, in 
its association with TFIIH, may have yet another function. 
Egly and coworkers (Roy et al., 1994) have proposed that 
this kinase may play a role in nucleotide excision repair, 
both in vivo and in vitro. It will be an enticing but difficult 
endeavor to determine whether, in vivo, different M015/ 
CDK7 complexes are involved in transcription and, per- 
haps, cell cycle regulation and DNA repair. 
As revealed by kinase assays with GST-CTD fusion pro- 
tein, M015/CDK7 appears to phosphorylate the CTD in 
a cooperative manner. We thus suspect that the initial 
phosphorylations trigger the rapid and complete phos- 
phorylation of the CTD. This begs the question of why the 
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initiation competent pol IIA isoform is unphosphorylated 
in spite of its close association with MO1 5/CDK7. The most 
straightforward explanation implies kinetic arguments. In 
rat liver, free unphosphorylated pol II (pol IIA) is far less 
abundant than transcriptionally engaged, phosphorylated 
pol II (pol 110) (Wuarin and Schibler, 1994), suggesting a 
rapid turnover of the pol IIA pool. It is tempting to speculate 
that CTD dephosphorylation is closely associated with 
transcription termination. Released pol II, once assembled 
into a holoenzyme, may spend very little time before reini- 
tiating transcription. This short transit time may not suffice 
for CTD phosphorylation. 
Negative superhelical turns have previously been re- 
ported to facilitate a step in transcription initiation that, 
with linear templates, requires the activity of TFIIE, TFIIF, 
and TFIIH (Parvin and Sharp, 1993). Originally, this step 
was believed to be isomerization. However, by using an 
abortive transcription assay, Goodrich and Tjian (1994) 
have demonstrated that negative supercoils assist pro- 
moter escape, rather than isomerization. Although the rat 
liver holoenzyme favors circular superhelical templates 
somewhat over linear templates, it is clearly capable of 
initiating on both templates. 
Two albumin promoters, one containing all of the up- 
stream sequences for maximal in vitro transcription and 
one truncated at position -59, were similarly active in pro- 
moting transcription by the pol II holoenzyme. This is in 
accordance with the observation that transcriptional acti- 
vators important for albumin in vitro transcription, such as 
HNFl and C/EBPa, did not copurify with the holoenzyme. 
At least some of the holoenzyme molecules also contain 
TAFZ50, TAFBO, and TAFs5. Given the high biochemical sta- 
bility of the mammalian TFIID complex (Dynlacht et al., 
1991), we suspect that additional TAFs are also coimmu- 
noprecipitated with the MO-l .l antibody. Since TAFs are 
important targets for transcriptional regulation, we consid- 
ered that the holoenzyme may respond to transcriptional 
activators. However, our first attempts with supplementa- 
tion of recombinant C/EBPP were fruitless. While this pro- 
tein efficiently stimulates transcription in unfractionated 
liver or spleen nuclear extracts (Descombes et al., 1990; 
V. O., unpublished data), it did not increase transcription 
by the holoenzyme. At present, several explanations can 
be offered for the failure of the holoenzyme to respond to 
E. coli derived CIEBPP. For example, ClEBPb may require 
posttranslational modifications or the aid of coactivators 
(such as CREB-binding protein, CBP; Kwok et al., 1994) 
that are not provided by the purified holoenzyme. Clearly, 
many additional experiments are required before we can 
reach firm conclusions with regard to these issues. 
The existence of a pol II holoenzyme has first been es- 
tablished in yeast, through genetic and biochemical stud- 
ies by the groups of R. Young and R. Kornberg (see Intro- 
duction). Unlike its yeast counterpart, the mammalian 
holoenzyme described in this paper does not require sup- 
plementation with TBP and TFIIE for successful in vitro 
transcription, as it already contains these components. 
We consider unlikely the possibility that this apparent dif- 
ference is physiolqgically relevant. Rather, it may be the 
result of the different techniques used in the preparation 
of the two holoenzymes. The yeast pol II holoenzyme was 
enriched by extensive chromatographic fractionation of a 
whole-cell lysate (Koleske and Young, 1994; Kim et al., 
1994), while the rat liver enzyme was obtained by a rapid 
immunopurification from concentrated extracts of highly 
purified nuclei. Perhaps, the interactions of pol II with 
TFIID and TFIIE are particularly susceptible to dilution and 
are broken during the lengthy purification procedure ap-’ 
plied to the yeast enzyme. In this context, we should men- 
tion that our nuclei purification protocol involves the me- 
chanical breaking of cells in a buffer containing 2 M  
sucrose (see Gorski et al., 1986). The high viscosity of 
this lysis buffer reduces diffusion, thereby minimizing leak- 
age of nuclear components into the cytoplasm during sub- 
cellular fractionation. It is possible that the techniques 
commonly used for cells grown in tissue culture, such as 
HeLa cells, would not readily allow the isolation of a tran- 
scriptionally competent holoenzyme. In a HeLa whole-cell 
extract, the components of the basal transcription machin- 
ery may not be sufficiently concentrated to maintain the 
integrity of the holoenzyme, while nuclear extracts, ob- 
tained from cells lysed by hypotonic shock, may be de- 
pleted in some components of the basal transcription ma- 
chinery. 
Several observations point toward a crucial role of the 
CTD in the assembly of pol II holoenzyme. First, the mutant 
phenotype of yeast cells expressing RNA polymerase with 
truncated CTDs can be suppressed by mutations in SRB 
proteingenes(Koleske etal., 1992; Thompson et al., 1993; 
Liao et al., 1995). Second, mammalian pol II with a trun- 
cated CTD responds poorly to most activators (Gerber et 
al., 1995). Third, only RPBl subunits with intact (or nearly 
intact) CTDs were recovered in the immunoprecipitation 
with the M015/CDK7 antibody. 
Our work cannot exclude the possibility that binding of 
an integral holoentyme to the promoter and stepwise as- 
sembly of several of its components at the promoter can 
occur in parallel. However, the frequently observed syner- 
gistic activation by multiple transcription factors could be 
more readily explained by involving a pol II holoenzyme. 
Such a large complex would offer more peptide surfaces 
interactingsimultaneouslywithdistinct transcriptional reg- 
ulatory proteins and would thus be a better partner for 
cooperative binding than its individual components (for 
review see Ptashne, 1988). Moreover, the existence of 
a transcription competent eukaryotic pol II holoenzyme 
would unify the concepts of transcription in eukaryotes 
and prokaryotes, in spite of the enormous difference be- 
tween the complexity of holoenzyme subunit structures. 
Experimental Procedures 
Nuclear Extract Preparation 
Highly purified rat liver nuclei were prepared as described by Licht- 
Steiner et al. (1987). The nuclear pellet was resuspended at 10 OD& 
ml in nuclear lysis buffer containing 10 m M  HEPES (pH 7.6), 100 m M  
KCI, 0.15 m M  spermine, 0.5 m M  spermidine, 0.1 m M  NaF, 0.1 m M  
Na3V04,O.l m M  EDTA, 1 m M  DlT, 0.1 m M  PMSF,  and 10% glycerol). 
NaCl was added to a final concentration of 0.4 M  to extract soluble 
nonhistone proteins. After 20 min on ice, the nuclear lysate was spun 
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at 36,000 rpm in a fixed angle Ti60 rotor for 60 min at 0°C to sediment 
insoluble chromatin components. Soluble proteins were precipitated 
by the addition of 0.3 g of solid (NH,),SOI per ml of supematant. After 
1 hr on ice, the ammonium sulfate precipitate was recovered by sedi- 
mentation at 36,000 rpm in a fixed angle Ti60 rotor for 30 min at 0°C. 
The pelleted proteins were resuspended in dialysis buffer (25 mM 
HEPES [pH 7.61, 100 mM KCI, 0.1 mM NaF, 0.1 mM Na3V04, 0.1 mM 
EDTA, 0.25 mM DTT, and 10% glycerol), in 5% of the original nuclear 
lysate volume, and dialyzed twice for 2 hr against 250 vol of the same 
buffer. After a 2 min centrifugation in an Eppendorf microfuge, the 
supernatant was divided into 100 VI aliquots, snap-frozen in liquid 
nitrogen, and kept under liquid nitrogen until use. The protein concen- 
tration was determined as described in Gorski et al. (1986). Typically, 
1 g wet weight of rat liver yields 100 pl of nuclear extract containing 
8-12 mg of protein/ml. 
Holoenzyme lmmunopurification 
Per assay, 0.5 pi of ascites fluid containing a monoclonal anti-human 
MO15 antibody (MO-l .I, Tassan et al., 1994) or control’antibody was 
incubated with 20 pl of a suspension containing magnetic beads 
coated with goat IgG anti-mouse IgG (Dynal M450) for 4 hr at 4’C. 
The beads were extensively washed in PBS containing 0.1% Triton 
X-100 and incubated with 50 pl of undiluted crude nuclear extracts 
for 1 hr at 4OC with gentle shaking. Subsequently, the beads were 
then washed three times with 400 PI of washing buffer (25 mM HEPES 
[pH 7.61, 50 mM KCI, 0.1 mM EDTA, 0.1 mM Na3V04, 0.1 mM NaF, 
10% glycerol, 0.1% Triton X-100). 
In Vitro Transcription 
In vitro transcription reactions were performed as described by Gorski 
et al. (1986) with either crude nuclear extract (20 ~1 assays) or purified 
holoenzyme immobilized on washed beads (10 @I to 20 ~1 assays). 
The assays contained typically 2 pg of template DNA and were incu- 
bated for 90 min at 37OC with gentle shaking. 
Plasmid Constructions 
The plasmid -59Alb400 was constructed from the plasmid -170 mut 
B Alb400 (Lichtsteiner and Schibler, 1989) by removing the sequences 
between -170 and -60. The plasmid -170 mut B Alb400 was digested 
with the restriction endonucleases EcoRl and Bglll, the resulting 5’ 
overhangs were filled in with Klenow polymerase, and the resulting 
blunt-ended DNA was religated with T4 ligase, before being used to 
transform competent E. coli cells. The plasmid -170Alb220 was ob- 
tained by removing approximately 180 bp of the G-free cassette from 
the Smal-digested plasmid -170Alb400 with Exolll and mung bean 
nuclease (Zhu and Clark, 1994). 
Protein Phosphorylation Assays 
The GST-CTD fusion protein was expressed and purified from E. coli 
as described (Peterson et al., 1992; V. 0. and U.S., unpublished data) 
and used as substrate (250 ng) in a reaction of 20 @I containing the 
MO-l.1 IP from 5 pl of nuclear extract, 20 mM HEPES (pH 7.6), 25 
mM MgC12, 8 mM CaC12, 0.25 mM DTT, 10 nM ATP corresponding to 
10 FCi [y-32P]ATP, with or without unlabeled ATP where indicated. The 
reaction was allowed to proceed for 15 min at 37OC, stopped by the 
addition of 2x Laemmli buffer, and the proteins were separated by 
SDS-PAGE (Laemmli, 1970). 
Other Methods 
Western blot analysis was done as described in Ossipow et al. (1993), 
except that immunocomplexes were visualized by using goat anti- 
mouse or goat anti-rabbit antibodies coupled to horseradish peroxi- 
dase by using the Amersham ECL kit. Antibodies against TAFZEO, TFIIEa, 
and TFIIB were purchased from Santa Cruz Biotechnology and used 
at a dilution of 400-fold. In the Western blot experiments with the other 
antibodies (provided by colleagues, see Acknowledgements), the fol- 
lowing dilutions were used: lO,OOO-fold for TBP, MO-1.1, and ~62: 
5,000-fold for CTD; 2,000-fold for TAFso, TAFs5, TFIIFRAPZO, HNFl, 
HNF4, and CIEBPa. Templates for in vitro transcription were prepared 
as described by Gorski et al. (1986). Recombinant human TBP was 
prepared as described by Chiang et al. (1984) and was used in electro- 
phoretic mobility shift assays with a double-stranded oligonucleotide 
(upper strand, 5’-CCTGAAGGGGGGCTATAAAAGGGGGT-3’) as de- 
scribed (Ossipow et al. 1993). 
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